Preclinical Safety Evaluation of a Recombinant AAV8 Vector for X-Linked Retinoschisis After Intravitreal Administration in Rabbits
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
X-linked retinoschisis (XLRS) is a retinal disease caused by mutations in the gene encoding the protein retinoschisin (RS1) and one of the most common causes of macular degeneration in young men. Currently, no FDA-approved treatments are available for XLRS and a replacement gene therapy could provide a promising strategy. We have developed a novel gene therapy approach for XLRS, based on the administration of AAV8-scRS/IRBPhRS, an adeno-associated viral vector coding the human RS1 protein, via the intravitreal route. On the basis of our prior study in an Rs1-KO mouse, this construct transduces efficiently all the retinal layers, resulting in an RS1 expression similar to that observed in the wild-type and improving retinal structure and function. In support of a clinical trial, we carried out a study to evaluate the ocular safety of intravitreal administration of AAV8-scRS/IRBPhRS into 39 New Zealand White rabbits. Two dose levels of vector, 2e(10) and 2e(11) vector genomes per eye (vg/eye), were tested and ocular inflammation was monitored over a 12-week period by serial ophthalmological and histopathological analysis. A mild ocular inflammatory reaction, consisting mainly of vitreous infiltrates, was observed within 4 weeks from injection, in both 2e(10) and 2e(11) vg/eye groups and was likely driven by the AAV8 capsid. At 12-week follow-up, ophthalmological examination revealed no clinical signs of vitreitis in either of the dose groups. However, while vitreous inflammatory infiltrate was significantly reduced in the 2e(10) vg/eye group at 12 weeks, some rabbits in the higher dose group still showed persistence of inflammatory cells, histologically. In conclusion, intravitreal administration of AAV8-scRS/IRBPhRS into the rabbit eye produces a mild and transient intraocular inflammation that resolves, at a 2e(10) vg/eye dose, within 3 months, and does not cause irreversible tissue damages. These data support the initiation of a clinical trial of intravitreal administration of AAV8-scRS/IRBPhRS in XLRS patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145 · cited 1×
“Recently, the results from three separate clinical trials for Leber’s congenital amaurosis (LCA) showed the safety of AAV2 in human patients (Bainbridge et al. , 2008; Cideciyan et al. , 2008; Maguire et al. , 2008).”
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924 · cited 2×
“Recently, the results from three separate clinical trials for Leber’s congenital amaurosis (LCA) showed the safety of AAV2 in human patients (Bainbridge et al. , 2008; Cideciyan et al. , 2008; Maguire et al. , 2008).”
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864 · cited 1×
“Adeno-associated viral (AAV) vectors have gained an increasing acceptance as potential gene delivery vehicles for many inherited and acquired human diseases (Bakay et al. , 2007; Bainbridge et al ., 2008; Cideciyan et al ., 2008; Maguire et al ., 2008; Marks et al ., 2010; Nathwani et al ., 2011).”
Boutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970
Ocular immune privilege: therapeutic opportunities from an experiment of nature
Streilein, J. W. (2003) · Nature Reviews Immunology · doi:10.1038/nri1224 · Cited by 807 · cited 1×
“Moreover, the existence of ocular immune privilege (Streilein, 2003) may reduce the likelihood of developing an immune response against the virus or its product, increasing thereby the effectiveness of the gene transfer.”
MacLaren, R. E., Groppe, M., Barnard, A. R., Cottriall, C. L., Tolmachova, T., Seymour, L., Clark, K. R., During, M. J., Cremers, F. P. M., Black, G. C. M., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62117-0 · Cited by 796 · cited 1×
“Two patients with the most advanced choroideremia had substantial gains in visual acuity and no safety concerns were reported (MacLaren et al. , 2014).”
Dalkara, D., Byrne, L. C., Klimczak, R. R., Visel, M., Yin, L., Merigan, W. H., Flannery, J. G., & Schaffer, D. V. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005708 · Cited by 734 · cited 1×
“However, recently, a novel engineered capsid-modified AAV2 virus proved to transduce sufficiently photoreceptors after intravitreal delivery (Dalkara et al. , 2013).”
Inner limiting membrane barriers to aav-mediated retinal transduction from the vitreous
Dalkara, D., Kolstad, K. D., Caporale, N., Visel, M., Klimczak, R. R., Schaffer, D. V., & Flannery, J. G. (2009) · Molecular Therapy · doi:10.1038/mt.2009.181 · Cited by 357
Jiang, H., Couto, L. B., Patarroyo-White, S., Liu, T., Nagy, D., Vargas, J. A., Zhou, S., Scallan, C. D., Sommer, J., Vijay, S., et al. (2006) · Blood · doi:10.1182/blood-2006-04-017913 · Cited by 330 · cited 1×
“It has been demonstrated indeed that even low levels of neutralizing antibodies can completely halt transduction with high titers of vectors (Jiang et al. , 2006; Scallan et al. , 2006).”
Scallan, C. D., Jiang, H., Liu, T., Patarroyo-White, S., Sommer, J. M., Zhou, S., Couto, L. B., & Pierce, G. F. (2006) · Blood · doi:10.1182/blood-2005-08-3229 · Cited by 271
Research works printed but not linked: 30
- 10.1167/iovs.06-0145 · doi:10.1167/iovs.06-0145
- 10.1227/01.neu.0000279944.12903.2c · DOI
- 10.1016/j.preteyeres.2010.03.004 · DOI · Paper page
- 10.1073/pnas.0807027105 · DOI · Paper page
- Dalkara D., 2013, Sci. Transl. Med., 189, 189ra76
- 10.1001/archopht.123.11.1563 · DOI
- 10.1073/pnas.182412299 · DOI · Paper page
- 10.1001/archophthalmol.2009.398 · DOI
- 10.1136/bjo.79.7.697 · DOI · Paper page
- 10.1001/archopht.125.4.571 · DOI
- 10.1093/hmg/9.12.1873 · DOI · Paper page
- 10.1182/blood-2003-02-0495 · DOI · Paper page
- 10.3109/02713683.2013.779720 · DOI · Paper page
- 10.1097/IAE.0b013e318030c517 · DOI
- 10.1002/jgm.1126 · DOI · Paper page
- Li Q., 2008, Mol. Vis., 14, 1760
- 10.1007/s00417-008-0765-z · DOI
- 10.1016/S1474-4422(10)70254-4 · DOI · Paper page
- Molday L.L., 2001, Invest. Ophthalmol. Vis. Sci., 42, 16
- 10.1038/gt.2009.61 · DOI · Paper page
- Sieving P.A., 2009, GeneReviews® [Internet], 1993
- 10.1111/j.1365-2567.2005.02239.x · DOI · Paper page
- 10.1038/mt.2008.41 · DOI · Paper page
- 10.1093/ilar.50.2.206 · DOI · Paper page
- 10.1167/iovs.04-0156 · DOI · Paper page
- Takada Y., 2006, Mol. Vis., 12, 1108
- 10.1126/scitranslmed.3002103 · DOI · Paper page
- 10.1038/nbt1073 · DOI · Paper page
- 10.1074/jbc.M413117200 · DOI
- 10.1167/iovs.04-0576 · DOI · Paper page
Cited by
Seitz, I. P., Michalakis, S., Wilhelm, B., Reichel, F. F., Ochakovski, G. A., Zrenner, E., Ueffing, M., Biel, M., Wissinger, B., Bartz-Schmidt, K. U., et al. (2017) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.17-22473 · Cited by 108
“Such a systemic visibility after IVT may promote vector recognition by the immune system and might help to explain any form of immune response after gene therapy.(11,18,19) Recent findings complement this hypothesis by showing a qualitative difference in immune response after IVT.”
Bush, R. A., Zeng, Y., Colosi, P., Kjellstrom, S., Hiriyanna, S., Vijayasarathy, C., Santos, M., Li, J., Wu, Z., & Sieving, P. A. (2016) · Human Gene Therapy · doi:10.1089/hum.2015.142 · Cited by 86
Self-citationTimmers, A. M., Newmark, J. A., Turunen, H. T., Farivar, T., Liu, J., Song, C., Ye, G.-J., Pennock, S., Gaskin, C., Knop, D. R., et al. (2020) · Human Gene Therapy · doi:10.1089/hum.2019.144 · Cited by 77
Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses
Ghoraba, H. H., Akhavanrezayat, A., Karaca, I., Yavari, N., Lajevardi, S., Hwang, J., Regenold, J., Matsumiya, W., Pham, B., Zaidi, M., et al. (2022) · Clinical Ophthalmology · doi:10.2147/opth.s364200 · Cited by 76
“Studies on humans and NHPs have demonstrated consistently that intravitreal delivery of vectors induces a significant humoral immune response.(13,21,75,76) The response is marked by the production of Abs, which may not lead to inflammation, but can significantly reduce the efficacy of treatment by attacking and elimin…”
BackgroundGene Therapy Intervention in Neovascular Eye Disease: A Recent Update
Lin, F.-L., Wang, P.-Y., Chuang, Y.-F., Wang, J.-H., Wong, V. H. Y., Bui, B. V., & Liu, G.-S. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.06.029 · Cited by 74
Metadata
- Authors
- Marangoni, D., Wu, Z., Wiley, H. E., Zeiss, C. J., Vijayasarathy, C., Zeng, Y., Hiriyanna, S., Bush, R. A., Wei, L. L., Colosi, P., & Sieving, P. A.
- Venue
- Human Gene Therapy Clinical Development
- Publisher
- SAGE Publications
- Published
- 2014-12
- Volume
- 25
- Issue
- 4
- Pages
- 202-211
- ISSN
- 2324-8637 (ISSN-L)
- 2324-8645
- OpenAlex
- W2329402578
- Cited by
- 29
- References
- 11
- FWCI
- 1.78
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.liebertpub.com/nv/resources-tools/text-and-data-mining-policy/121/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Preclinical Safety Evaluation of a Recombinant AAV8 Vector for X-Linked Retinoschisis After Intravitreal Administration in Rabbits. https://app.cochat.ai/papers/10.1089/humc.2014.067
- The paper
- Marangoni, D., Wu, Z., Wiley, H. E., Zeiss, C. J., Vijayasarathy, C., Zeng, Y., Hiriyanna, S., Bush, R. A., Wei, L. L., Colosi, P., & Sieving, P. A. (2014). Preclinical Safety Evaluation of a Recombinant AAV8 Vector for X-Linked Retinoschisis After Intravitreal Administration in Rabbits. Human Gene Therapy Clinical Development. https://doi.org/10.1089/humc.2014.067
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.